Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi

Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has announced a significant expansion of its ongoing Phase 2 clinical trials for KT-474. This decision, influenced by positive preliminary safety and efficacy data reviewed by an Independent Data Review Committee, was communicated by Sanofi, Kymera’s strategic partner. […]

Suven Life Sciences announces promising results at 76th American Academy of Neurology Meeting

Suven Life Sciences announces promising results at 76th American Academy of Neurology Meeting

Suven Life Sciences, a clinical-stage biopharmaceutical company focused on the development of novel treatments for Central Nervous System (CNS) disorders, is set to present significant study results at the 76th American Academy of Neurology (AAN) Annual Meeting. The event will take place from April 13 to 18, 2024, in Denver, USA, as well as virtually. […]